Dr. Annette C. Fontaine, MD

Dr. Fontaine practices at Surgical Specialty Care in Albuquerque, New Mexico.

Dr. Fontaine's NPI, 1346234788, was assigned on August 31, 2005. Dr. Fontaine holds New Mexico license 2005-0639.

Dr. Fontaine's primary practice is Surgical Specialty Care, at 4901 Lang Ave Ne, Albuquerque, NM 87109. The practice phone is (505) 842-8171.

Dr. Fontaine's primary practice is Surgical Specialty Care in Albuquerque, New Mexico. Dr. Fontaine is also affiliated with Presbyterian Hospital. The medical group on file is New Mexico Cancer Center (NMCC). Dmand AI also links Dr. Fontaine to 4 more hospitals, 1 group practice or clinic, 1 therapy and rehab clinic and 1 medical group, each named with a free account. Dr. Fontaine's employer is on file too: a surgery center (asc).

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Fontaine practices, 8 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Fontaine's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Fontaine is licensed in New Mexico.

CMS data shows 29,896 Medicare services from Dr. Fontaine across 47 procedure codes in 2024, for 676 Medicare patients. Medicare paid $457,427 for them.

CMS counts 676 Medicare patients who saw Dr. Fontaine in 2024. The largest group is 65 to 74, with 307 patients. 67% of them have high blood pressure, and 64% have high cholesterol. 15% are also on Medicaid. Their average risk score is 1.88, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Fontaine's median patient age at 69, with 66% women.

In 2024, Dr. Fontaine wrote 1,628 Medicare Part D claims for 261 patients. 74% of them were for generic drugs. CMS names the drug for 1,241 of them, across 36 drugs with 11 or more claims each, at $3,151,363 in total drug cost. In 2023, CMS named 1,408 claims across 44 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Fontaine for performance year 2024, reported as part of a group. Dr. Fontaine accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Fontaine as offering telehealth.

Dmand AI links 3 papers to Dr. Fontaine, published from 2015 to 2024. The most frequent topics are Breast Neoplasms, Genetic Predisposition to Disease and Ovarian Neoplasms. Dr. Fontaine's most frequent co-authors are Noah D. Kauff, MD, Antonis Antoniou, MD and Banu K. Arun, MD.

Dmand AI links Dr. Fontaine to 2 clinical trials. 1 is still active or recruiting. Conditions studied include Graft vs Host Disease, Neoplasm Metastasis and Immune System Diseases.

CMS Open Payments shows 392 general payments to Dr. Fontaine from 58 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 81% of the total. Daiichi Sankyo Inc. paid the most, $87,774.